HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M300201-JLR200v1 44/11/2100    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verseyden, C. Articles by Cabezas, M. C. Search for Related Content PubMed PubMed Citation Articles by Verseyden, C. Articles by Cabezas, M. C. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 44, 2100-2108, November 2003
Copyright © 2003 by American Society for Biochemistry and Molecular Biology

Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia

C. Verseyden^*, S. Meijssen^*, H. van Dijk, H. Jansen and M. Castro Cabezas^1,*

^* Departments of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Biochemistry, Erasmus Medical Center, Rotterdam, The Netherlands

¹ To whom correspondence should be addressed. e-mail: m.castrocabezas{at}azu.nl

VLDL overproduction by enhanced hepatic FFA flux is a major characteristic of familial combined hyperlipidemia (FCHL). The postprandial complement component 3 (C3) response has been associated with impaired postprandial FFA metabolism in FCHL. We investigated the effects of 16 weeks of treatment with atorvastatin on postprandial C3 and lipid changes in 12 FCHL patients. Atorvastatin significantly lowered fasting plasma C3 and triglyceride (TG) in FCHL. Fasting TG and insulin sensitivity were the best predictors of fasting and postprandial C3. Postprandial triglyceridemia and C3 response, estimated as area under the curve (AUC), were significantly lowered by atorvastatin by 19% and 12%, respectively, albeit still elevated, compared with 10 matched controls. Postprandial FFA-AUC and postheparin plasma lipolytic activities remained unchanged after atorvastatin, suggesting no major effect on lipolysis. After atorvastatin, postprandial hydroxybutyric acid-AUC, which was elevated in untreated FCHL patients, was decreased, reaching values similar to those in controls.

The present data show reduction of postprandial hepatic FFA flux in FCHL by atorvastatin, providing an additional mechanistic explanation for the reduction of VLDL secretion reported previously for atorvastatin. This was accompanied by a decrease in fasting plasma C3 concentrations and a blunted postprandial C3 response to an acute oral fat load.

Supplementary key words chylomicron • postprandial lipemia • free fatty acid • insulin resistance • acylation-stimulating protein

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. P. H. van Wijk, M. C. Cabezas, E. J. P. de Koning, T. J. Rabelink, R. van der Geest, and I. M. Hoepelman In Vivo Evidence of Impaired Peripheral Fatty Acid Trapping in Patients with Human Immunodeficiency Virus-Associated Lipodystrophy J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3575 - 3582. [Abstract] [Full Text] [PDF]

				C. Verseyden, S. Meijssen, and M. C. Cabezas Effects of Atorvastatin on Fasting Plasma and Marginated Apolipoproteins B48 and B100 in Large, Triglyceride-Rich Lipoproteins in Familial Combined Hyperlipidemia J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5021 - 5029. [Abstract] [Full Text] [PDF]